As well as the research on laser-assisted lipolysis, Cynosure’s technology is highlighted in the next presentations at the ASLMS Annual Meeting: A Prospective Research of the Improvement in Peri-Orbital Lines and wrinkles and Eyebrow Elevation with a Novel Fractional CO2 Laser, Bruce E. Katz, M.D., Clinical Professor, Mt. Sinai School of Medication, Director, JUVA Skin & Laser Center, Director, PLASTIC SURGERY & Laser beam Clinic, Mt.announced today that the U.S. A Priority Review designation is given to drugs that may offer major advancements in treatment, or provide a treatment where no sufficient therapy exists. If acceptance is definitely granted, Alexion anticipates that Soliris would be designed for U.S. Patients with aHUS in the 4th quarter of 2011. The European Medicines Agency can be reviewing a marketing software for Soliris as cure for patients with aHUS in europe. Both the US and EU sBLA submissions are the positive data from both 26-week Phase 2 studies of Soliris as a treatment for adult and adolescent patients with aHUS. Main endpoints in both scholarly research were achieved with statistical significance.